drugset / Trial / NCT02677623

Evaluation of Ureteral Patency in the Post-indigo Carmine Era

NCT02677623

Phase 4 Completed 140 enrolled Columbia University
RandomizedParallel-groupOpen-labelDiagnostic

Summary

Many gynecologic, urologic and pelvic reconstructive surgeries require accurate ways to identify the opening of the ureters to ensure that they are working correctly. Historically, indigo carmine, an intravenous medication that dyes the urine blue, has been used to help visualize the opening of the ureters with cystoscopy which is a camera placed inside the bladder. In June 2014, the FDA announced there was current shortage of indigo carmine. Thus, investigators need to evaluate other methods for assessing ureteral patency. Ideal alternatives are agents that are low-risk, inexpensive, provide comparable visualization, are readily available and are easy to use. Examples of such agents currently being used to evaluate the ureters, include oral pyridium, IV sodium fluorescein, and mannitol. These agents help identify the opening of the ureters by either dyeing the urine a different color such as pyridium and sodium fluorescein, or by having a different viscosity to urine such as mannitol. This study will compare three methods of evaluating ureteral patency at time of cystoscopy compared to no method: mannitol, sodium fluorescein, and pyridium.

Timeline

Start
2015-03
Primary completion
2016-08
Completion
2016-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Mannitol Diagnostic / imaging agent 300 ml Other
Subject Phenazopyridine Small molecule 200 mg Oral
Subject Sodium Fluorescein Diagnostic / imaging agent 25 mg Intravenous

Indications

No indication recorded.